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The taming of oxygen: biocatalytic
oxyfunctionalisations
Dirk Holtmann,a Marco W. Fraaije,b Isabel W. C. E. Arends,c Diederik J. Oppermand
and Frank Hollmann*c
The scope and limitations of oxygenases as catalysts for preparative organic synthesis is discussed.
Introduction
Selective oxyfunctionalisation of non-activated hydrocarbons repre-
sents a contemporary issue of organic chemistry. The inertness of
most C–H bonds requires powerful oxygen transfer agents.1 High
activity, however, is frequently accompanied by poor selectivity,
which is in contrast to the demands of modern chemical synthesis.2
Nature provides us with a class of catalysts that comprises both
features: activity and selectivity: Oxygenases catalyse the introduc-
tion of oxygen atoms from molecular oxygen or hydrogen peroxide
into (non-)activated C–H- and CQC-bonds and to heteroatoms.
Often, these oxyfunctionalisation reactions occur highly selectively.
Many oxygenases are selective for only one position in structurally
complex molecules and they introduce the oxygen atoms with
high stereocontrol. Furthermore, overoxidation, which is a frequent
problem in chemical oxyfunctionalisation, is far less observed
in enzymatic oxyfunctionalisations. This unique combination of
activity and selectivity stems from the embedding of reactive oxygen
transfer reagents such as highly oxidised iron–oxo complexes
or organic peroxides in the cavity of an enzyme’s active site. The
well-defined and chiral environment not only positions the starting
material precisely to the ‘hot’ oxygen atom transferred (accounting
for selectivity) but also stabilises transition states thereby leading
to, sometimes dramatic, rate accelerations as compared to the
biomimetic analogues (Scheme 1).
Therefore, it is not very astonishing that the interest in
biological oxyfunctionalisation chemistry has been steadily grow-
ing over the past decades. We are convinced that oxygenases,
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following the well-established hydrolases4–6 and the ever more
popular dehydrogenases,5,7–10 will represent the next upcoming
wave of biocatalysts used in chemical synthesis.11
The aim of this perspective is to encourage organic chemists
to consider oxygenases in their synthesis planning more often.
For this, we will focus on the application of oxygenases for
organic synthesis, giving an overview over the rich product
spectrum available already today and discussing some recent
preparative examples. In particular, we will cover the most-
common oxygenases, i.e. flavin-dependent monooxygenases as
well as heme-dependent monooxygenases and -peroxygenases.
Also some perceived and real limitations en route to becoming truly
practical catalysts, together with some promising solutions will be
discussed. A detailed discussion of the catalytic mechanisms
would be beyond the scope of this perspective; the interested
reader is referred to some excellent reviews5,6,12–14 exhaustively
covering our current mechanistic understanding.
It is also worth mentioning here that continuously new
oxygenases are discovered as well as existing ones are improved
to match with the requirements of chemical synthesis.1,10,12,14–35
Again, an in-depth discussion of these approaches, let alone the
new enzymes obtained is not possible here, but some excellent
recent contributions exhaustively cover this field.
Flavin-dependent monooxygenases
Flavin-dependent monooxygenases represent an extremely diverse
class of enzymes catalysing an equally diverse range of synthetically
useful oxyfunctionalisation reactions (Scheme 2).28–30,33,36–40
The catalytic mechanism of the flavin-dependent monooxy-
genases comprises an oxidative and a reductive half reaction.
The catalytic cycles start with the latter by NAD(P)H-mediated
reduction of the enzyme-bound flavin group. The reduced
Scheme 1 Oxygenases comprise highly reactive oxygenation agents
such as (formal) FeV-oxyferryl-heme, or (hydro)peroxo-flavins embedded
in the well-defined framework of an enzyme.3
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flavin interacts with molecular oxygen to form an organic
peroxide (C4a-(hydro)peroxoflavin), which acts as the actual
oxygen transfer agent (oxidative half reaction). The resulting
C4a-hydroxyflavin eliminates water and thereby returns to the
oxidized resting form (Scheme 3). Only very recently an alternative
mechanism for oxygenation by a flavoprotein has been revealed.41
It was shown that the bacterial enzyme EncM, involved in
the biosynthesis of the antibiotic enterocin, performs an
coenzyme-independent oxygen insertion via a reactive flavin
N5-oxide. In this specific example, the reducing equivalents
come from the substrate itself. It remains to be seen whether
this is a rare example or whether there are more flavoproteins
in nature that employ such a mechanism.
In principle, the chemical versatility of flavins should also allow
for H2O2-driven oxyfunctionalisation reactions as frequently
demonstrated with N5-alkylated flavins as ‘chemical catalysts’.28
Recently, Fraaije and coworkers have demonstrated that flavo-
proteins can be engineered to act as peroxygenases by replacing
the riboflavin cofactor in the riboflavin-binding protein with
alkylated flavins. Overall the general feasibility of ‘flavoperoxy-
genases’ could be demonstrated (Scheme 4).42
Organic chemists are probably most acquainted to the enzymatic
Baeyer–Villiger oxidation mediated by so-called Baeyer–Villiger
monooxygenases (BVMOs, Scheme 2, 2). Since some early contribu-
tions from the mid-20th century43–45 and the pioneering work by
Trudgill and coworkers46,47 the scope of enzymatic Baeyer–Villiger
reactions has been expanded significantly in the last two dec-
ades31,48–50 and a range of synthetically useful transformations have
been reported (Table 1). Also, the first crystal structure of a BVMO51
has significantly contributed to the mechanistic understanding of
BVMOs52,53 and enabled rational approaches to engineer tailored
new BVMOs.54–64 Today, the enzymatic Baeyer–Villiger oxidation
(in the form of whole cell biotransformation, vide infra) has reached
the multi-kg scale65–68 and further scale-ups and industrial applica-
tions may be expected in the nearer future.
A special case of BVMO-catalysed Baeyer–Villiger oxidations
is the oxygenation of aldehydes (Scheme 2, 5). In most cases,
BVMOs convert aldehydes into the corresponding formyl esters
(following the migration rules of the chemical Baeyer–Villiger
oxidation). However, recently Bisagni and coworkers reported
Scheme 2 4a-(Hydro)peroxoflavin as the active species leading to the diverse reactions catalysed by flavin-dependent monooxygenases. (1) Epoxidation
of CQC-double bonds, (2) Baeyer–Villiger oxidation of (cyclic) ketones, (3) ortho- and para-hydroxylation of phenols, (4) heteroatom oxygenation,
(5) oxidation of aldehydes, and (6) halogenation reactions.
Scheme 3 Simplified catalytic cycle of flavin-dependent monooxy-
genases. In the resting state of the enzyme the reduced nicotinamide
cofactor (NAD(P)H) binds to the enzyme and transfers its hydride to the
alloxazine moiety (1). In step (2) the reduced flavin reacts with molecular
oxygen yielding the catalytically active (hydro)peroxoflavin, which, in step
(3) performs the oxyfunctionalisation reaction. The resting state is regen-
erated after water extrusion (step (4)). Please note that for reasons of
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on a novel BVMO from Dietzia sp. preferentially catalysing acid
formation of e.g. profene aldehydes.69
Many of the aforementioned BVMOs are also capable of hetero-
atom oxygenation (Scheme 2, 4). Enantiospecific sulfoxidation here
clearly represents the reaction most frequently investigated.30,70–74
Next to the often high enantioselectivity of this reaction, also its
high chemoselectivity is valued as the ‘overoxidation product’
i.e. the corresponding sulfone is usually not observed in enzymatic
sulfoxidation reactions. Next to sulphur also other heteroatoms
such as selenium,75–78 boron,77,79 or nitrogen48 can be oxygenated
using flavin-dependent monooxygenases. Recently, Codexis
evolved cyclohexanone monooxygenase for the selective sulfoxida-
tion to yield enantiopure (S)-pantoprazole (Scheme 5),74,80 thereby
impressively demonstrating the potential of protein engineering
to tailor a monooxygenase to meet the requirements of industrial-
scale synthesis.
Also the regioselective hydroxylation of phenols (Scheme 2, 3)
either in the ortho- or para-position represents a principally highly
interesting reaction for organic synthesis as the repertoire of
chemical aromatic hydroxylations (apart from Dakin-, Sandmeyer-
and Baeyer–Villiger-type reactions as well as boronic acid oxida-
tions) is rather limited. However, at present also the number of
phenol hydroxylases is rather restricted as well.81 Nevertheless
for example, 2-hydroxy biphenyl-3-monooxygenase (HbpA) has
been used at up to kg-scale synthesis of catechols.82–89 But also
phenol hydroxylase (PheA1),90–93 and the benzoate hydroxy-
lases94–96 have been reported and might exhibit some synthetic
potential.
Stereoselective epoxidation of CQC-double bonds (Scheme 2, 1)
is an emerging field in flavoprotein-monooxygenase chemistry.
Especially the so-called styrene monooxygenases are enjoying
increased popularity. For example the styrene monooxygenase
from Pseudomonas sp. VLB 120 has been investigated inten-
sively by Schmid and coworkers.97–114 But also new styrene
monooxygenases from other sources are constantly added to
the portfolio.32,115–121
Currently, the styrene monooxygenases available appear to have
a clear preference for vinyl aromatic substrates even though also
aliphatic alkenes have been reported as substrates.119,120 The more
severe limitation of the present portfolio is that exclusively (S)-
selective styrene monooxygenases are known. Hopefully, screen-
ing of natural diversity and/or protein engineering will close
this gap in the nearer future.
An interesting cascade reaction producing enantiomerically
pure (S)-styrene oxide from (renewable) phenylalanine in a cascade
of amino lyase, decarboxylase and styrene monooxygenase was
reported recently by Nielsen and coworkers (Scheme 6).122
Also, flavoprotein monooxygenase-catalysed oxidative halo-
genation reactions (Scheme 2, 6) are worth mentioning here. In
the stricter sense, these reactions are not oxyfunctionalisation
reactions as a halogen is incorporated instead of an oxygen
atom.123–133 According to our present knowledge, flavin-
dependent halogenases primarily catalyse the oxidation of
halogenides to hypohalous acids (HOCl, HOBr). These are
guided by the protein backbone directly and exclusively to the
substrate performing the electrophilic halogenation reaction.
Even though, flavin-dependent halogenases seem to be limited
to activated (aromatic) substrates, their exclusive regioselectiv-
ity should make them highly interesting tools not only for
pharmaceutical applications. However, en route to preparative
application their still comparably poor catalytic activity (kcat
being in the range of o1 min1) needs to be addressed.
Very recently, an interesting cascade of tryptophan synthase
and tryptophane-7-halogenase was reported giving access to
a broad range of tryptophan derivates from simple indole
starting materials (Scheme 7).134
Finally, also a newly discovered long-chain alkane degrading
flavoprotein monooxygenase (LadA) should be mentioned
here.135,136 So far, this is the only flavin-dependent mono-
oxygenase reported capable of hydroxylating non-activated
hydrocarbons (being largely the domain of (non)-heme iron
monooxygenases, vide infra). At present, only a few reports deal
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Table 1 Representative examples of oxyfunctionalisation reactions mediated by flavin-dependent monooxygenases
Substrate Product R
% Conv.






(87) SMO (rec ingrowing E. coli) 499 (S) 1 L
[S]0 = 695 mM;
t = 8 h 100
R1 = H,
R2 = Me
95 (87) SMO (crude
cell extract)
99.7 (S) 100 mL [S]0 = 50 mM;
t = 10 h;
TON(SMO) = 1844
114
R1 = R2 = H,









1 mL [S]0 = 200 mM;t = 24 h 119 and 120
R1 = R3 = H,
R2 = Cl
91 (73) SMO (crude
cell extract)
499.9 (S) 100 mL [S]0 = 50 mM;
t = 10 h;
TON(SMO) = 2171
114
(50) SMO (rec inresting E. coli)
499 epoxide
(de = 98%) 20 mL
[S]0 = 4,5 mM;
t = 2 h 137 and 138
n = 1 (48) SMO (rec ingrowing E. coli) 98 (S) 1 L
[S]0 4 150 mM;
t = 19 h 112
n = 2 (53) SMO (rec in
growing E. coli)
98.5 (S) 1 L [S]0 4 150 mM;
t = 45 h
112




Z98 (R) 10 mL [S]0 = 12 mM;t = 48 h 139
(2) Baeyer–Villiger oxidations
499 (58) CHMO (rec ingrowing E. coli)
99% (1R,5S)
97 (1S,5R) 50 L
900 g;
[S]0 4 0.1 M;




([S]total = 36 mM);
t = 7 h
140
499 PAMO (partiallypurified enzyme) 499 (S) 13 mL
[S]0 4 20 mM;








50 mL KR; [S]0 = 5.4 mM 141








E 4 200 1 mL
KR or
desymmetrization;
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with this interesting enzyme and future will tell the preparative
potential of LadA.
A representative selection of examples ranging from analytical
proof-of-concept contributions to (near) industrial scale imple-
mentations is shown in Table 1.
Overall, flavin-dependent monooxygenases have great potential
for organic synthesis. They enable highly selective introduction
of molecular oxygen into organic compounds. Very often, a
comparable chemical route is yet unknown. Unfortunately, at
present only a few of these promising catalysts are commer-
cially available (e.g. some BVMOs).
Heme-iron-monooxygenases and
-peroxygenases
Heme-iron-monooxygenases, also called P450- or CYP-
monooxygenases, exhibit an even higher oxyfunctionalisation
Table 1 (continued )
Substrate Product R
% Conv.
(% yield) Catalyst ee (%)
Volumetric
scale Remarks Ref.
(3) Phenol hydroxylation reactions





[S]0 = 160 mM;







1 mL [S]0 = 50 mM;t = 8 h 92 and 143
499 PheA1 (rec ingrowing E. coli) 50 mL
[S]0 = 5 mM;









[S]0 = 10 mM;






E = 23 0.5 mL KR; [S]0 = 10 mM;t = 24 h 79
(45) SMO (rec inresting E. coli) 54.5 (S) 1 mL
[S]0 = 200 mM;
t = 24 h 119 and 120
SMO: styrene monooxygenase; CHMO: cyclohexanone monooxygenase; BVMO: Baeyer–Villiger monooxygenase; PAMO: phenylacetone monooxygenase;
HAPMO: 4-hydroxyacetophenone monooxygenase; HbpA: 2-hydroxy biphenyl-3-monooxygenase; PheA1: phenol hydroxylase; 3HB6H: 3-hydroxy
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potency than most of the flavoprotein monooxygenases discussed
above. P450 monooxygenases can also abstract non-activated C–H
bonds such as in alkanes. Obviously, this has inspired many
research groups worldwide to explore the catalytic potential of this
enzyme class (Scheme 8).20,21,144–147
P450 monooxygenases comprise a somewhat more compli-
cated mechanism than flavoprotein monooxygenases. Molecular
oxygen is activated by coordination to a highly oxidized (formally
FeV) iron species enabling electrophilic O-transfer. To achieve this,
two additional reducing equivalents are necessary, which are deliv-
ered in two individual single electron transfer steps (Scheme 9).
Again, NAD(P)H serves as a source for the reducing equiva-
lents needed. However, since NAD(P)H is an obligate hydride
donor, it is not capable of interacting directly with the iron
centre (being an obligate single electron acceptor). To overcome
the mechanistic incompatibility of NAD(P)H and Fe3+, nature
uses e.g. NAD(P)H-ferredoxin oxidoreductases as relay systems.
These enzymes contain flavins, which due to their mechanistic
versatility, can accept a hydride from NAD(P)H and pass on
the two electrons in two subsequent steps either to the mono-
oxygenase directly or via electron transport proteins such as
Fe2S2 ferredoxin (Scheme 10).
It is worth mentioning here that some P450 monooxygenases
are capable of forming the catalytically active oxyferryl species from
the resting state using hydrogen peroxide (Scheme 9). However,
usually, their eﬃciency with H2O2 is relatively poor so that oxidative
inactivation of the heme-prosthetic group (and the protein back-
bone) dominates. In contrast, the so-called peroxygenases utilise
this hydrogen peroxide shunt pathway very eﬃciently enabling the
H2O2-driven P450-oxyfunctionalisation chemistry. In fact, it has
been hypothesised that the P450 monooxygenases have evolved
from H2O2-dependent ancestors.
158
P450 monooxygenases have received tremendous attention
due to their capability to hydroxylate non-activated C–H bonds.
For example, the selective and mild hydroxylation of (cyclo)-
alkanes represents a focus of research. The promise here lies in
the high selectivity of the enzymatic hydroxylation avoiding
undesired overoxidation of the (more reactive) reaction products
as frequently encountered in (industrial) oxidation methods.159 A
very recent contribution by Gro¨ger and coworkers nicely demon-
strates the synthetic potential of biocatalytic oxyfunctionalisation
(Scheme 11).160,161 By combining a P450-monooxygenase with an
alcohol dehydrogenase, the authors achieved clean aerobic oxida-
tion of cyclohexane to cyclohexanone with absolute selectivity.
Scheme 5 Cyclohexanone monooxygenase (CHMO)-mediated enantiospecific sulfoxidation for the synthesis of (S)-pantoprazole.
Scheme 6 Cascade from natural phenylalanine to (S)-styrene oxide entailing phenylalanine ammonia lyase (PAL), phenoloic acid decarboxylase (PADC)
and styrene monooxygenase (SMO).
Scheme 7 Cascade for the synthesis of unnatural halogenated tryptophanes from simple indoles. TrpS: tryptophan synthase; Trp7-Hal: tryptophan-7-
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The overall low yield of the reaction (o10%) is most probably
attributed to the volatility of the reagents and the non-optimised
reaction conditions. Nevertheless, the high selectivity of this
reaction convinces especially compared to chemical processes,
where frequently by-products originating from overoxidation
and ring-cleavage are observed.159
Scheme 8 Compound I as the active species leading to the diverse reactions catalysed by P450-monooxygenases and peroxidases. (1) Hydroxylation of
(non)activated C–H-bonds148–153 even of methane;154,155 (2) hydroxylation of aromatics;156 (3) epoxidation of CQC-double bonds; (4) carbene transfer
to CQC-double bonds (actually starting from the reduced FeII stage and not being an oxyfunctionalisation reaction).157
Scheme 9 Simplified catalytic cycle of P450-monooxygenases. The catalytic cycle starts with binding of the substrate to the resting (FeIII) state of the
enzyme followed by single electron transfer (from NAD(P)H via the electron transport chain), O2-binding and the second electron transfer. The resulting
hydroperoxo iron is dehydrated after successive protonation resulting in a (formal) FeV–oxo species (compound I) performing the O-transfer reaction.
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Similar examples comprise the selective transformation of
(cyclo)alkanols into the corresponding esters (e.g. cyclohexanol
to e-caprolactone).162,163
Industrial interest in P450 monooxygenases today mainly
stems from the pharmaceutical industry for the generation
of drug metabolites and the production of active pharma-
ceutical ingredients (APIs) such as steroids.26,146,147,164,165
But also selective oxyfunctionalisation of terpenes is of great
interest.152,166–173
A very elegant approach was reported by Keasling and
coworkers who used an engineered Saccharomyces cerevisiae
overexpressing a P450 monooxygenase to produce artemisinic
acid (basically from sugar) (Scheme 12).174,175
Often, P450 monooxygenase-catalysed reactions are still
somewhat too slow and yield too low product titers (vide infra)26
to meet the economic requirements for bulk chemicals.176
Nevertheless, oxyfunctionalisation of fatty acids to yield
a,o-dicarboxylic acids (as polymer building blocks) has been
demonstrated at appreciable product titres of more than
100 g L1 (ref. 177–180) pointing towards large-scale applic-
ability of these biocatalysts.
For a long time, methane hydroxylation was believed to be
limited to non-heme iron monooxygenases and out of scope for
P450-monooxygenases. Especially the higher bond-strength of
the methane C–H bond as compared to higher homologues was
thought to be the major reason for this.154 However, recently
Reetz and coworkers have demonstrated that inert decoy molecules
such as perfluorinated acids enable the P450BM3-catalysed hydro-
xylation of even methane.155 It is thought that the perfluorinated
alkyl chain ‘fills up’ the large cavity around the active site and
thereby facilitates methane binding. The same approach (decoy
molecules) was also successful in enhancing P450BM3-catalysed
hydroxylation of e.g. benzene.156,181 It is also interesting to note that
such decoy molecules may have an influence on the stereo-
selectivity of P450-catalysed oxyfunctionalisation reactions.182
Next to protein engineering20,158,164,183–189 also substrate
engineering may be a promising approach to improve P450-
monooxygenase-catalysis as demonstrated by Griengl and
coworkers.190–193 For example Beauveria bassiana cannot convert
cyclopentanone whereas the corresponding N-benzoylspiro-
oxazolidine was converted smoothly by the same organism
(Scheme 13).
It was suggested that the starting material itself was not
eﬃciently recognised by the monooxygenase. Also the nature of
the temporary protecting group had an influence on the stereo-
selectivity of the hydroxylation reaction. So far, this approach has
not found widespread and systematic investigation.
Another exciting new development in P450-chemistry is the
recent finding by Arnold and coworkers that reduced (FeII) P450
Scheme 10 Transformation of a hydride transfer reagent (NAD(P)H) into
two single electron transfer reagents (e.g. ferredoxin, Fd). NAD(P)H:ferredoxin
oxidoreductase catalyse the oxidation of NAD(P)H (by hydride transfer to the
enzyme-bound flavin cofactor, step (1)). The reduced flavin than successively
delivers one electron each to two ferredoxins (Fd).
Scheme 11 Bi-enzymatic cascade for the selective aerobic oxidation of
(cyclo)alkanes to the corresponding ketones using a sequence of P450
monooxygenase-catalysed hydroxylation (here P450BM3 from Bacillus
megaterium) and ADH-catalysed further oxidation to the ketone.
Scheme 12 Engineered Saccharomyces cerevisiae overexpressing a P450 monooxygenase (CYP71AV1) for the selective (triple) oxygenation of
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monooxygenases are eﬃcient cyclopropanation catalysts
(Scheme 14), opening up new avenues for P450-chemistry.157
Table 2 gives a representative, yet naturally incomplete,
overview over the diversity of P450 monooxygenase-catalysed
oxyfunctionalisation reactions.
Peroxygenases entail the chemical versatility of P450 mono-
oxygenases without being dependent on the complicated electron
transport chains (vide infra). Instead of relying on reductive
activation of molecular oxygen, peroxygenases utilise H2O2 to
form the catalytically active oxyferryl species (hydrogen peroxide
shunt in Scheme 9).197
For many decades chloroperoxidase from Caldariomyces
fumago (CPO) has been the role model and only representative
of this highly interesting enzyme class.198–227 However, more
recently a range of new (and potentially more useful) members
of this enzyme class have gained interest.228–244 For example
a peroxygenase from the basidomycetous fungus Agrocybe
aegerita is capable of cyclohexane hydroxylation, a reaction that
has never been observed for CPO.228 If developed further, this
reaction might become a viable alternative to the existing,
selectivity-wise highly challenging chemical cyclohexane oxygenation
reactions.159
Even though peroxygenases are most valuable for the
organic chemist due to their oxygen transfer capability (yielding
e.g. enantiomerically pure epoxides or sulfoxides), some other –
potentially very useful – applications have been reported recently.
Haloperoxidases, for example, catalyse the oxidation of halo-
genides and release of the corresponding hypohalogenide into
the reaction medium. Recently, Le Noˆtre, Scott and coworkers
reported a ‘biocatalytic’ oxidative decarboxylation of natural
amino acids such as phenyl alanine yielding the corresponding
nitriles as the major product (Scheme 15).245 The role of the
vanadium peroxidase was restricted to in situ formation of
hypochloride, which mediated the oxidative decarboxylation
of the a-amino acid. Compared to a stoichiometric use of
bleach, this catalytic method excels by its catalytic use of
chloride thereby significantly reducing salt wastes.
Some of us have applied CPO recently for the chemoenzy-
matic halogenation of thymol. The hydrogen peroxide needed
for the enzymatic reaction was generated by electrochemical
reduction of molecular oxygen (Scheme 16) thereby providing
H2O2 in suﬃcient amounts to sustain the catalytic cycle while
minimising H2O2-related inactivation of the enzyme.
Overall, P450-enzymes (monooxygenases and peroxygenases)
exhibit enormous potential for preparative organic synthesis.
Regeneration strategies
As mentioned above, reduced nicotinamides serve as universal
electron donors for the reductive activation of molecular oxygen.
Therefore, it is not very astonishing that the majority of published
applications include NAD(P)H. Due to its fairly high costs, NAD(P)H
cannot be applied in stoichiometric amounts but rather in catalytic
amounts together with a suitable cofactor regeneration system
(Table 3). Overall, oxidation of a simple sacrificial cosubstrate is
utilised to promote monooxygenase catalysis.
One obvious approach is to utilise the microbial
metabolism to provide the reducing equivalents
needed.65,97,98,100,103–105,111–113,137,138,140,246–250 The advantages
of this approach are: (1) the enzyme(s) are not isolated thereby
significantly reducing the catalyst preparation costs,176 the same is
true for the nicotinamide cofactor, which is supplied by the micro-
bial cell; (2) generally, enzymes within their natural environment
(the microbial cell) are more stable than as isolated preparations,
also the microbes can constantly replace inactivated enzymes; (3)
the growth substrate (e.g. glucose) for themicroorganism also serves
as a sacrificial electron donor for the biotransformation reaction
thereby theoretically providing the maximal amount of reducing
equivalents available from complete mineralisation. These advan-
tages explain why fermentative processes still dominate the field of
biocatalytic oxyfunctionalisation chemistry. There are, however,
also a range of challenges that have fostered research on the use
of isolated enzymes. Amongst them are the frequently observed
toxicity of the reagents to the microbial cells, transport limita-
tions of reagents over the cell membranes, as well as issues
related to undesired side reactions catalysed by the many other
enzymes present in the microbial cells. Also, it is not always easy
to balance the microorganism’s redox needs with the demands
of the desired biotransformation.
Using isolated monooxygenases circumvents some of the
aforementioned challenges: by utilising isolated enzymes, the
Scheme 13 Eﬀect of temporary attachment of an oxazolizine protection
group to cyclopentanone on the biohydroxylation by B. bassiana.
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biotransformation is uncoupled from the fermentation step
and therefore can be controlled more easily. Also, undesired
side reactions are generally observed to a lesser extent than in
whole-cell systems. The major challenge of using isolated
enzymes is that the supply of the monooxygenase with reducing
equivalents does not anymore come along with the microbial
metabolism. Hence, the nicotinamide cofactor (in substoichio-
metric amounts) has to be applied together with a suitable in situ
regeneration system. Table 3 gives an overview on common
enzymatic NAD(P)H regeneration systems used to promote
Table 2 Representative examples of P450-catalysed oxyfunctionalisation reactions
Substrate Product Yield Catalyst ee (%)
Volumetric
scale
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monooxygenase reactions. To estimate the eﬃciency of a given
regeneration system the total turnover number (TTN) of the
nicotinamide cofactor can be used. As a rule of thumb, TTN of
greater than 1000 are generally considered to be suﬃcient for
an economically reasonable process (even though it must be
mentioned here that this very much depends on the price of the
product amongst others).
Recently, so-called designer cells have gained significant
attention. This approach combines the advantages of whole
cell biocatalysis and the regeneration approaches outlined in
Table 3 by coexpressing the production enzyme together with a
suitable regeneration system and using the whole cells as
catalysts.120,252 On the one hand the enzymes are protected in
their natural environment and also protein-isolation and
-purification is not applied. On the other hand, the cells are
usually not metabolically active thereby largely eliminating
toxicity issues as well as undesired side reactions. Overall, the
designer-cell approach appears to be a very promising catalyst
concept for future biocatalytic oxyfunctionalisation reactions.
The regeneration approaches outlined before all are based on
the enzyme-coupled regeneration concept: regeneration reaction
and production reaction are linked via the nicotinamide cofactor
only. Hence, the cofactor regeneration consumes another sub-
strate (cosubstrate) and produces a stoichiometric coproduct.
Another interesting approach is the so-called intrasequential
cascade, wherein the NAD(P)H-consuming (oxyfunctionalisation)
reaction is also productively coupled to the NAD(P)H-regenerating
reaction via an intermediate product (Scheme 17). Their use
elegantly circumvents the need for the additional cosubstrate–
coproduct couple by double transformation of only one substrate
but naturally is rather limited in scope. However, the self-sufficient
nature of these reactions as well as the apparent non-generation
Scheme 15 Vanadium-haloperoxidase catalysed oxidative decarboxylation of phenylalanine.
Scheme 16 Chemoenzymatic halogenation of phenols (e.g. thymol) using CPO-generated hypochloride. H2O2 was obtained in situ from electro-
chemical O2 reduction.
Table 3 Examples for enzymatic NAD(P)H regeneration systems used for monooxygenase reactions
Regeneration enzyme Cosubstrate Coproduct Cofactor Ref.
FDH Formate CO2 NADH 86, 114, 173 and 251
ADH Isopropanol Acetone NADPH 62 and 120
PDH Phosphite Phosphate NAD(P)H 148, 252 and 253
G6PDH Glucose-6-phosphate Glucono-6-phosphate lactone NAD(P)H 40 and 254–256
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of wastes might point towards bulk-scale application such as
e-caprolactone or cyclohexanone from simple starting materials.
Direct regeneration approaches
Many monooxygenases rely on rather complicated, multi-
enzyme electron transport chains to deliver the reducing
equivalents from NAD(P)H to the flavin- or heme-prosthetic
group. While this architecture makes sense for the (microbial)
cell as it adds further levels of control over the cellular redox
metabolism, it adds further complexity to the application of
monooxygenases for chemical synthesis. Often, only the reducing
equivalents are needed to sustain the monooxygenases’ catalytic
cycles; therefore in recent years a growing number of research
eﬀorts have been dedicated to delivering the reducing equivalents
directly to the monooxygenases and circumventing the electron
transport chains (Scheme 18).
The potential benefit of such direct regeneration approaches
is that complicated electron transport chains comprising up to
2 additional enzymes and 2 additional cofactors can be sub-
stituted by only one regeneration catalyst, resulting in highly
simplified (and more easily controllable) reaction schemes.
Table 4 summarises some representative examples of oxy-
functionalisation reactions performed by direct regeneration.
It becomes clear from Table 4 that the immense potential of
direct regeneration of monooxygenases still remains to be exploited.
The major limitation is the regeneration catalysts, which in most
cases do not appear to act as true catalysts. We believe that the
reason lies in the high reactivity of most mediators with molecular
oxygen. Hence, futile reoxidation of the reduced regeneration cata-
lysts bymolecular oxygen competes with the desiredmonooxygenase
regeneration thereby lowering the productive catalytic turnover of
the regeneration catalysts. Furthermore, the futile cycle leads to the
generation of reactive (partially reduced) oxygen species (ROS), which
impair enzyme stability and lead to undesired side reactions.
The molecular reason for this undesired side reaction
probably lies in the redox properties of the regeneration catalysts
used.With the exception of [Cp*Rh(bpy)(H2O)]
2+ and deaza-flavin, all
regeneration catalysts are obligate one electron donors; hence their
reaction with the predominant triplet oxygen (3O2) is spin-allowed
(and fast) whereas the reactions of the two-electron donors
([Cp*Rh(bpy)H]+ and deaza-flavinred) with 3O2 are spin-forbidden
(and therefore slow). Also the natural redoxmediators such as putida
redoxin (Pdx) are single electron mediators and therefore prone to
fast aerobic reoxidation. The same is true to some extent for reduced
flavins. Even though they are traditionally denoted as two-electron
donors (in the classical mechanisms) they are also able to
form semiquinones e.g. during sequential reduction of FeS-
redoxproteins or during fast synproportionation with oxidised
flavins.274 This also explains the exceptionally high turnover
numbers observed by Schmid and coworkers (Table 4).101
Scheme 17 Examples of intrasequential oxyfunctionalisation sequences with the monooxygenase catalysing the second (A)162,163 or the first step
(B)160,161 of the sequence.
Scheme 18 Comparison of the ‘traditional’ regeneration of multi-component monooxygenases (upper) with the direct regeneration approach (lower).
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By using very low flavin concentrations they could eﬃciently
shift the flavin synproportionation equilibrium away from the
reactive flavin semiquinones. Furthermore the advanced elec-
trochemical reactor setup enabled minimising the contact time
of reduced flavins and molecular oxygen.
Unfortunately, so far this undesired uncoupling reaction
(also observed quite frequently with the ‘traditional’ regeneration
approaches) has not been addressed very much and a general
awareness of this oxygen dilemma is missing.
Overall, it can be asserted that on the one hand undesired,
spontaneous reduction of molecular oxygen leads to a waste of
reducing equivalents and concomitant of toxic ROS. On the other
hand, molecular oxygen, as an integral part of the catalytic cycle of
monooxygenases, cannot be omitted form the reaction schemes,
resulting in the ‘oxygen dilemma’. Practical solutions to the oxygen
dilemma are urgently needed in order to make monooxygenase-
catalysis truly practical for organic synthesis.
Supply with H2O2 to promote peroxygenase catalysis
The dependence of peroxygenases on simple peroxides only at first
sight oﬀers a trouble-free catalyst system to be used in organic syn-
thesis. The major challenge of using peroxides as a source of oxygen
lies in their reactivity, especially with the prosthetic heme group itself.
The exact inactivation mechanism is still under debate but it is clear
by now that already small concentrations of hydrogen peroxide
irreversibly inactivate the heme group (most probably oxidatively).275
The simplest approach to circumvent the undesired oxidative
inactivation of peroxygenases is to supply H2O2 in various, small
portions. This approach is, however, work-intensive and also leads
to significant volume increases which will complicate downstream
processing. Alternatively, organic hydroperoxides have received
some attention as milder alternatives to H2O2.
197 More recently,
various in situ O2 reduction methods have been evaluated to
generate H2O2. The principle behind is that these methods enable
to generate H2O2 in situ in just the right amounts to sustain
peroxygenase catalysis while minimising the H2O2 related inactiva-
tion. Table 5 gives an overview of the diﬀerent sources of reducing
equivalents needed for O2 reduction and catalysts used.
Each H2O2 generation method has specific advantages and
disadvantages. For example, cathodic reduction of molecular oxygen
represents a potentially very simple and environmentally benign
approach, but also requires specialised equipment. Glucose oxidase
mediated reduction of O2 is simple and easy to apply, however
gluconic acid accumulates in stoichiometric amounts leading to
challenges in pH control. Overall, ‘the ideal’ in situ H2O2 generation





Today, biocatalysis is generally accepted as a ‘green technology’.
Often, one or a few of the famous Twelve Principles of Green
Chemistry288 are used to substantiate the green touch of a given
Table 4 Examples for direct regeneration of monooxygenases





P450 cam Pdx Cathode 0.06 259
StyA FAD Cathode Up to 700 101, 108 and 260
StyA [Cp*Rh(bpy)(H2O)]
2+ NaHCO2 10 110
Myoglobin None Cathode — 261 and 262
P450 cam Pdx Cathode 0.51 263
P450rFP45004A1 Co(sep) Cathode 0.016 264
P450BM3 Co(sep) Zn o1 265 and 266
P450BM3 [Cp2Co]
+ Cathode 0.05 267
P450BM3 Co(sep) Zn 0.15 266
P450BM3 – Ru-hybrid catalyst Sodium
diethyldithiocarbamate
140 153 and 268
P450BM3 Deazaflavin EDTA 7 269
P450BM3 Co(sep) n.d. Cathode 168 and 270–272
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biocatalytic reaction. However, we are convinced that authors
should be more careful with green claims as a critical evalua-
tion of the environmental impact might actually result in nasty
surprises. The Twelve Principles of Green Chemistry are a
wonderful framework for the design of environmentally more
friendly processes but simple adherence to some of these principles
does not make a given reaction/process ‘green’. Therefore, a more
quantitative (and critical) evaluation is a prerequisite en route to
truly Green Chemistry. Today, full life cycle assessment, taking into
account as many parameters as possible, represents the ‘golden
standard’ of environmental evaluation. However, the data basis
required for LCAs is enormous, making LCAs time-consuming and
too expensive for academics to perform.
We believe that simple, mass-basedmetrics such as the E-factor
(E being the amount of waste generated per kg of product)289 may
be a valuable tool especially for academic researchers to estimate
the ‘greenness’ of a given reaction.290–293 The E-factor concept
is easily understood and the calculations easily and quickly
done. Of course, such a simple mass-based tool neglects
important contributors to the environmental impact such as
energy consumption and does not weigh the quality of the
different mass flows (scarce starting materials, hazardous
wastes).294,295 Nevertheless, the E-factor frequently qualitatively
points into the same direction as more advanced analyses and
thereby can give valuable hints to optimise a reaction.100,290,296
Therefore, we would like to encourage especially academic
researchers to use this simple tool more often to critically
assess the environmental impact of their reactions.
In the following, we highlight and discuss two Green Chemistry
issues that – to our mind – are notoriously underestimated in the
scientific literature dealing with (bio)catalytic oxyfunctionalisation
chemistry: substrate loading and downstream processing.
Substrate loading has a very significant impact on the
economic feasibility and environmental impact of a reaction.
However, themajority of reactants of interest is poorly water soluble.
Unfortunately, the general solution to this challenge is to apply the
startingmaterial in low concentrations (often in the lowermillimolar
range). A simple E-factor estimation however demonstrates the
dimensions of the water ballast resulting from this (Fig. 1). Produ-
cing tons of contaminated waste water per kg of product cannot be
the ultimate green (not to mention economical) solution.
Increasing the overall substrate concentration can significantly
reduce the water ballast of any given reaction and therefore
should be more often be strived for. To cope with the poor
substrate solubility, the two-liquid-phase-system (2LPS) approach
seems to be a viable solution. Here, a water-immiscible apolar
organic phase serves as the substrate reservoir and product sink
enabling overall high payloads (Scheme 19).
Additional benefits from the 2LPS concept may be alleviation of
reactant toxicities and inhibitory eﬀects (especially for whole cell
biocatalysts),100,297 prevention of over-oxidation (e.g. of aldehydes
into carboxylic acids),11,100,246,297–303 and prevention of hydrolytic
degradation of e.g. epoxide or lactone products.14,111,112,114,304–306
Furthermore, high product concentrations in easily water separable
organic phases will also facilitate DSP (vide infra).
Of course, the selection of the organic solvent should –next
to practical issues such as partitioning coefficients and bio-
catalyst stability – also take its potential environmental impact
into account.307–309
Table 5 In situ H2O2 generation methods to promote peroxygenase reactions
Catalyst Cosubstrate Coproduct Ref.
GOx Glucose Gluconolactone 197, 211 and 276–279
Cathode — — 201 and 280–284
Pd H2 — 285
Flavin/hn EDTA Ethylene diamine, CO2, formaldehyde 228, 286 and 287
GOx: Glucose oxidase.
Fig. 1 Water consumption at diﬀerent reactant concentrations (expressed
as kg(wastewater) per kg(product)). Black line: theoretical Water-E-factor
(assumption M(product) = 200 g mol1, full conversion); red diamonds:
experimental Water-E-factors from published monooxygenase reactions,290
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One issue of 2LPS arises from the rather hydrophilic char-
acter of many sacrificial electron donors used such as formates,
phosphites or glucose making them incompatible with 2LPSs
exhibiting high volumetric ratios of organic to aqueous phase.
To solve this challenge, some of us have recently proposed
using hydrophobised formates as the organic phase for bioca-
talytic oxyfunctionalisation reactions (Scheme 20).251
Downstream processing (DSP) is an issue that is not
very frequently addressed in typical publications dealing
with (bio)catalysis. However, DSP is an integral part of the
production system as ‘it is no product unless it is in a bottle’
(C. Wandrey). From an environmental point-of-view, DSP can
contribute very significantly to the overall environmental
impact of a production system.290,310 Therefore, an increased
focus on DSP issues also at an early stage of development is
highly desirable. This should include ‘smart by design’ reaction
systems enabling facile product isolation e.g. by filtration or
2LPSs enabling low-energy distillation DSP.
Another very promising line of research comprises so-called
cascade reactions,311,312 wherein complex reaction sequences
are performed without isolation of the intermediate reaction
products. A very elegant cascade was reported recently by
Bu¨hler and coworkers reporting a formal terminal amination
of fatty acids by combining a sequence of two hydroxylase- and
one transaminase-reaction (together with the corresponding
cofactor regeneration reactions) in one engineered E. coli pro-
duction strain (Scheme 21).313,314
Today, still too many research projects on biocatalytic
oxyfunctionalisation focus on the biocatalyst only while accepting
low substrate loadings and completely neglecting the DSP part.
Conclusions
Biocatalysis has a lot to oﬀer for the organic chemist. Simple
and robust catalysts such as lipases for chirotechnology appli-
cations are well-established already. Oxygenases are on the go
to follow them. This will significantly broaden the chemist’s
toolbox for selective oxidation/oxyfunctionalisation reactions.
Especially the high selectivity of enzymes will enable shorter
Scheme 19 The two-liquid phase system (2LPS) approach. A hydro-
phobic organic phase solubilises overall high amounts of the hydrophobic
reactants. From there, the substrate partitions into the aqueous,
oxygenase-containing aqueous phase to be converted. The product,
again, partitions between both phases and thereby is largely extracted
into the organic layer.
Scheme 20 Hydrophobic formic acid esters as the reactive organic phase serving as the substrate reservoir/product sink and source of reducing
equivalents for FDH-catalysed NADH regeneration.
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synthesis routes and yield higher quality products. Another
interesting feature of biocatalysis (in general) is its potential
for environmentally more benign syntheses. However, being
biobased alone does not make an enzymatic route green, a
more self-critical evaluation of contributors is highly desirable.
In this respect, already simple metrics such as the E-factor may
be valuable and simple tools.
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